5-Aminolevulinic acid photodynamic therapy is a safe and effective treatment for female patients with intractable vulvar lichen sclerosus

• Published in: Photodiagnosis and photodynamic therapy Vol. 49; p. 104330
• Main Authors: Zheng, Xiangrong, Liu, Xiaoli, Zhang, Junhua, Liu, Hongli, Xu, Ying, Meng, Lihua, Zhang, Youzhong, Wang, Lili, Jia, Lin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-10-2024; Elsevier
• Subjects: 5-aminolevulinic acid; Adult; Aged; Aminolevulinic Acid - therapeutic use; Conservative treatment; Female; Humans; Intractable vulvar lichen sclerosus; Middle Aged; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - therapeutic use; Quality of Life; Retrospective Studies; Vulvar Lichen Sclerosus - drug therapy; Photodynamic therapy; Intractable vulvar lichen sclerosus; 5-aminolevulinic acid; Conservative treatment
• ISSN: 1572-1000; 1873-1597; 1873-1597
• DOI: 10.1016/j.pdpdt.2024.104330

•ALA-PDT significantly improved VLS patients’ clinical symptoms and signs.•The side effects of ALA-PDT for VLS were transient and tolerable which led to high patients’ satisfaction.•ALA-PDT is a safe and effective treatment for women with intractable VLS.
Female vulvar lichen sclerosus (VLS) is a chronic inflammatory skin disease of the vulva and its etiology is unknown. The main clinical symptoms are itching, burning and dyspareunia, and there is a lack of effective treatment.
Clinical and follow-up data of women with VLS who underwent 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) from January 2023 to December 2023 in the department of obstetrics and gynecology, Qilu Hospital of Shandong University, were retrospectively analyzed. According to the inclusion and exclusion criteria, 36 patients with VLS who received ineffective conventional treatment (intractable VLS) were enrolled. Objective signs and subjective symptoms of vulvar lesions were recorded before treatment and 6 months after the end of treatment according to corresponding scoring criteria. Quality of life was evaluated using the Dermatology Life Quality Index (DLQI).
All patients received six sessions of ALA-PDT treatment and follow-up visits. After ALA-PDT treatment, 24 of 36 (66.67 %) patients' itching symptoms completely disappeared, 10 of 36 (27.78 %) patients' itching symptoms were relieved from severe to mild, and only 2 of 36 (5.56 %) patients' symptoms were not significantly relieved. 16 of 36 (44.4 %) patients' itching symptoms completely disappeared, 9 of 36 (25 %) patients' itching symptoms were relieved from severe to mild, and only 2 of 36 (5.56 %) patients still had severe pain. Compared to 22 patients with dyspareunia before treatment, only 9 patients still had dyspareunia with varying degrees of dyspareunia relief after treatment. Clinical signs improved significantly in the patients after ALA-PDT treatment. The total scores of clinical signs were (5.31 ± 1.67 vs 3.67 ± 1.71) before and after treatment. All patients showed improvement in DLQI after treatment. The main side effects of ALA-PDT were pain, erythema and swelling which were transient and tolerable. All patients were “satisfied” or “very satisfied” with the results of the treatment.
ALA-PDT is a safe and effective treatment for women with intractable vulva lichen sclerosus.